Those ovarian cancer patients with high expression of PDGFRβ and VEGFR2 might particularly benefit from additional anti-vascular therapy such as anti-VEGF antibodies or novel tyrosine kinase inhibitors targeting PDGFR and VEGFR. The gene discussed is VEGFA; the disease is ovarian carcinoma.